tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Hu RH et al. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. 2000 Transplant. Proc. pmid:11119894
Tzakis AG et al. Two-year experience with FK 506 in pediatric patients. 1993 Transplant. Proc. pmid:7679822
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. 1994 Transplant. Proc. pmid:7513476
Yashima J et al. Successful conversion from tacrolimus to cyclosporine after kidney transplantation. 2000 Transplant. Proc. pmid:11119895
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Machado PG et al. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation. 2002 Transplant. Proc. pmid:11959207
Jain A et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. 1998 Transplant. Proc. pmid:9636567
Chang HY et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. 2013 Jan-Feb Transplant. Proc. pmid:23375324
Zervos XA et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplant. Proc. pmid:9636568
Matevossian E et al. Liver transplantation in the rat: single-center experience with technique, long-term survival, and functional and histologic findings. 2009 Jul-Aug Transplant. Proc. pmid:19715990
Müller H et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. 2008 Transplant. Proc. pmid:18454992
Sekido H et al. Successful conversion from cyclosporine to tacrolimus for immunosuppression. 2000 Transplant. Proc. pmid:11120096
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
de la Fuente S et al. Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events: analysis of 30 cases. 2014 Transplant. Proc. pmid:25420837
Perrella A et al. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. 2010 Transplant. Proc. pmid:20534267
Meçule A et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. 2010 Transplant. Proc. pmid:20534290
Alloway R et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848559
Peddi VR et al. Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9636626
Tellis V et al. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation. 2005 Transplant. Proc. pmid:15848571
Chen JS et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. 2009 Transplant. Proc. pmid:19545678
Akbas SH et al. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients. 2004 Jan-Feb Transplant. Proc. pmid:15013308
Bakar F et al. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus. 2009 Transplant. Proc. pmid:19545695
Cabello M et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. 2010 Transplant. Proc. pmid:20970603
Marcén R et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. 2010 Transplant. Proc. pmid:20970609
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Demetris AJ et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. 1993 Transplant. Proc. pmid:7505503
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Tullius SG et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. 2003 Transplant. Proc. pmid:14529854
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Manu MA et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. 1999 Transplant. Proc. pmid:10578313
Mucha K et al. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil. 2003 Transplant. Proc. pmid:14529880
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Woodle ES et al. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. 1993 Transplant. Proc. pmid:7682360
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Woo J et al. Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. 1991 Transplant. Proc. pmid:1721319
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Ito Y et al. Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection. 2002 Transplant. Proc. pmid:12176430
Loucaidou M et al. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919456
Ping X et al. Antigen sampling on the Peyer's patches in a murine small bowel transplantation model. 2010 Transplant. Proc. pmid:21094860
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Altaca G et al. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. 2002 Transplant. Proc. pmid:12270320
Tanabe K et al. Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. 2002 Transplant. Proc. pmid:12176493
Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. 2002 Transplant. Proc. pmid:12176495
Ramirez CB et al. Early steroid withdrawal after liver transplantation. 1998 Transplant. Proc. pmid:9838406
Ko WJ et al. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. 1998 Transplant. Proc. pmid:9838474
Shapiro R Tacrolimus (FK-506) in kidney transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123077
Borda B et al. Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia. 2011 Transplant. Proc. pmid:21620104
Cho JH et al. Chronic rejection in pediatric liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123078
Reggiani P et al. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation. 1996 Transplant. Proc. pmid:8907965
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Jiang H et al. FK 506 and deoxyspergualin: additive immunosuppressive effect on rat cardiac allograft rejection in vivo and mitogen-stimulated human lymphocyte responses in vitro. 1994 Transplant. Proc. pmid:7520631
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Wada Y et al. Expression of the transcriptional factor egr-1/BTEB2 in cardiac xenograft vascular remodeling. 2000 Transplant. Proc. pmid:10936371
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
Krzyżowska K et al. No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients. Transplant. Proc. pmid:30056895
Zmonarski S et al. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient. Transplant. Proc. pmid:30056893
Beaunoyer M et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. 2002 Transplant. Proc. pmid:12176540
Kim K et al. Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104132
McAlister VC et al. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. 1999 Feb-Mar Transplant. Proc. pmid:10083495
Lee S et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. 2010 Transplant. Proc. pmid:20430174
Kim JM et al. Preemptive therapy in adult liver transplant recipients in CMV-endemic area. 2010 Transplant. Proc. pmid:20430182
Ali IH et al. Incidence and risk factors for post-renal transplant diabetes mellitus. 2011 Transplant. Proc. pmid:21440763
Basadonna GP et al. Pancreas after kidney transplantation: HLA mismatch does not preclude success. 1997 Feb-Mar Transplant. Proc. pmid:9123470
Kato Y et al. Epidermal growth factor enhances the intestinal adaptation of small bowel allografts in the postoperative period. 2000 Transplant. Proc. pmid:10995935
Kimura O et al. Influence of bombesin on the intestinal mucosal immunologic response under immunosuppression. 2000 Transplant. Proc. pmid:10995942
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Rigotti P et al. Antilymphocyte induction is no longer necessary in simultaneous pancreas and kidney transplantation. 2002 Transplant. Proc. pmid:12176623
Dette K et al. Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome. 2002 Transplant. Proc. pmid:12176624
Salazar A et al. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. 2001 Feb-Mar Transplant. Proc. pmid:11267181
Zaltzman J et al. Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267183
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Heffron TG et al. Daclizumab induction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267408
Pretagostini R et al. Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience. 2016 Transplant. Proc. pmid:27109947
Rabkin JM et al. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267411
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Dall'Agnol DJ et al. Effects of immunosuppressive drugs on gastrointestinal transit of rats: effects of tacrolimus, cyclosporine, and prednisone. Transplant. Proc. pmid:25131057
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
McAlister VC Liposomal tacrolimus: drug migration within blood compartments. 1998 Transplant. Proc. pmid:9636404
Rong G et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. 2010 Transplant. Proc. pmid:21094796
Barak S et al. Alveolar bone height in patients after liver transplantation. 2000 Transplant. Proc. pmid:10856558
van Hooff JP et al. Preservation of renal function and cardiovascular risk factors. 2006 Transplant. Proc. pmid:16979974
Guleria S et al. Tacrolimus (Pan Graf) as de novo therapy in renal transplant recipients in India. 2006 Transplant. Proc. pmid:16979989
Shapiro R The development of tacrolimus in renal transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750356
Morris-Stiff G et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. 1998 Transplant. Proc. pmid:9636506